All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Trillium Therapeutics Inc., of Toronto, priced an underwritten public offering of 2.75 million shares and 3.25 million series II nonvoting convertible first preferred shares.
